T-Heart Appoints Sarah Sorrel as Independent Board Member
T-Heart, a medtech company developing a truly novel and differentiated transcatheter tricuspid prosthetic heart valve specifically designed for tricuspid regurgitation, today announced it has appointed Sarah Sorrel as its first independent member of the Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221129005579/en/
(Photo: T-Heart)
Sarah Sorrel has more than 30 years’ experience in medical device regulation and clinical trials with an emphasis on emerging technologies. She founded and successfully managed MedPass International, a leading European CRO, regulatory and reimbursement consultancy, that specializes in medical device development and market access, before its acquisition by ICON plc in 2020. Sarah is American and holds a degree in Engineering and Applied Science from Yale University.
Sarah Sorrel joins the T-Heart Board of Directors when the company is preparing its First in Human / Early Feasibility Study, bringing a valuable experience and expertise to its execution. Soad El Ghazouani, CEO of T-Heart said: “We are excited to have an independent board member with such considerable experience in medtech, and more specifically in the transcatheter heart valve field, joining the board at T-Heart at a key moment for the company. Sarah’s experience and extensive knowledge of healthcare regulations will be an invaluable asset as we advance towards the clinic.”
Ms. Sorrel added: “I am honored to join the T-Heart Board of Directors and convinced that tricuspid is the next key step in the transcatheter heart valve field. I look forward to contributing to T-Heart’s important objective to bring a perfectly adapted and differentiated solution to patients suffering from severe tricuspid regurgitation and hopefully significantly improve their quality of life. “
Ms. Sorrel is the third female out of five representatives to join the board of T-Heart.
ABOUT T-HEART
T-Heart is a French MedTech company focused on the treatment of Tricuspid Regurgitation, a true medical unmet need. Tricuspid regurgitation is a progressive condition in which blood leaks backward through the tricuspid valve, potentially leading to heart failure and death. The transcatheter tricuspid market represents a $3.0+ billion potential opportunity, although currently, limited treatment options exist to address this market.
T-Heart has developed a truly novel and differentiated transcatheter tricuspid prosthetic heart valve specifically designed for tricuspid heart valve regurgitation, thereby addressing the specific anatomical challenges. Moreover, T-Heart's unique design enables the interventional cardiologist to replace the diseased tricuspid valve with a simple one-step technique and allows for broad applicability to a larger patient population with minimal device sizes.
T-Heart was co-founded in late 2018 with iBionext, a company builder and investor that supports and finances the development of companies with a strong technological breakthrough in HealthTech in Paris, France.
Since its inception, T-Heart has assembled an impressive team, comprised of management and external experts, has successfully proved the concept through pre-clinical testing and initiated its Q-Sub for EFS with the FDA.
For more information:
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221129005579/en/
Contact information
T-HEART
Soad El-Ghazouani +33 (0)1 85 73 27 05
selghazouani@theartvalve.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ramboll and Acutro Form Strategic Alliance to Drive Smarter, More Sustainable Intelligent Buildings21.1.2026 09:13:00 EET | Press release
Ramboll, a global leader in engineering, architecture, and consultancy, has entered into a strategic, collaborative partnership with Acutro, specialists in building performance improvement and predictive, data-led maintenance. The partnership brings together Ramboll’s global engineering expertise and Acutro’s digital building intelligence capabilities, creating synergies that support innovation, learning, and value creation for both organisations and their clients. The collaboration enables Ramboll to explore advanced building intelligence tools that can strengthen its digital design capability, while providing Acutro with the opportunity to apply and evolve its platform across complex, real-world projects. Together, the partners will help clients make more informed decisions about performance, lifecycle value, and operational risk. The multi-year relationship provides Ramboll with access to Acutro’s cloud-native platform, creating opportunities to integrate real-time performance analy
STREAMWIDE Marks Major APAC Milestone with UPCAD Public Safety Deployment in the Philippines21.1.2026 09:00:00 EET | Press release
STREAMWIDE has been selected by UPCAD (Unified Platform for Communication and Dispatch) of the Philippines to power its next generation critical communications platform for first responders integrated with national 911 call centers. Through this collaboration, UPCAD integrates STREAMWIDE’s field proven mission critical technology with the national 911 services, the new solution is designed to ensure uninterrupted, secure, and reliable communication during emergencies, enabling faster response times, improved situational awareness, and enhanced public safety outcomes. By integrating directly with 911 call centers, the platform enables real-time sharing of critical information such as caller location, incident details, and response status with first responders and command teams. Through our API, the platform integrates digital workflow capabilities, allowing information to flow seamlessly into the same system. This enables up-to-date reporting while automatically creating incident workfl
H2SITE Launches Norwegian Subsidiary to Accelerate Ammonia-to-Power and Maritime Decarbonisation21.1.2026 08:00:00 EET | Press release
H2SITE has launched H2SITE Norway AS, a new subsidiary based in Bergen, to enable the future of maritime hydrogen solutions. The company’s presence in Norway reflects its intention to work closer to the maritime and offshore industry and to support the practical deployment of hydrogen-based solutions for vessel decarbonisation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120617713/en/ H2SITE Ammonia Cracking Solution H2SITE is a Spanish scale-up company headquartered in Bilbao, where the core of its technology is designed and manufactured. From its industrial facility in Loiu (Bizkaia), H2SITE produces thousands of palladium-alloy membranes each year, which are integrated into membrane reactor systems enabling efficient conversion of hydrogen carriers back into hydrogen. In the case of ammonia, H2SITE has developed cracking systems capable of delivering high-purity hydrogen that can be supplied directly to fuel cells o
2026 Japan Prize Laureates Announced21.1.2026 07:00:00 EET | Press release
The Japan Prize Foundation announced the winners of the 2026 Japan Prize at 1:00 p.m. (JST) on 21 January 2026. Prof. Cynthia Dwork (USA) has been awarded the Japan Prize in the field of Electronics, Information, and Communication. Prof. Shizuo Akira (Japan) and Prof. Zhijian "James" Chen (USA) have been awarded the Japan Prize in the field of Life Sciences. For this year’s Japan Prize, Prof. Dwork is being recognized for her Contribution to leading research for building an ethical digital society, including differential privacy and fairness. Prof. Akira and Prof. Chen are being recognized for their Discovery of the nucleic acid sensing mechanism by the innate immune system. For the 2026 Japan Prize, the Foundation asked approximately 16,000 prominent scientists and engineers from around the world to nominate researchers working in this year’s fields. We received 107 nominations for the field of Electronics, Information, and Communication, and 185 nominations for the field of Life Scie
Ant Group’s AI Health Service AQ Upgrades PC Platform with DeepSearch for Evidence-Based Clinical Decision Support21.1.2026 05:12:00 EET | Press release
Ant Group today announced a major upgrade to the PC platform of its AI-native health assistant, AQ, introducing DeepSearch for clinicians, a new capability designed to support evidence-based clinical decision-making. The service is available free of charge to clinicians and medical students. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120591991/en/ AQ’s PC platform provides medical professionals with two core capabilities: Health Q&A and DeepSearch. It supports medical literature search, clinical practice, and research, helping reduce clinicians’ day-to-day workload while improving access to high-quality medical information. To ensure accuracy and reliability, AQ rigorously curates its sources based on recognized levels of evidence. The platform integrates more than 36 million high-quality Chinese and international medical publications, making its clinical decision support closely aligned with real-world practice. Deep
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom